BiotechTube
InnovHeart

InnovHeart

Milan, Italy· Est.
innovheart.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

InnovHeart is a private, clinical-stage medical device company targeting the significant unmet need in mitral valve disease, specifically mitral regurgitation (MR). Its lead program, the Saturn TMVR system, has entered early feasibility studies in Europe, with first-in-human trans-septal implantation reported in 2024 and initial patient results published in 2025. The company is positioning itself in a multi-billion dollar market opportunity by developing a transcatheter solution tailored to the mitral valve's complex anatomy, leveraging the commercial success of transcatheter aortic valve replacement (TAVR) as a roadmap. Leadership combines founding technical expertise with seasoned industry executive experience.

Cardiovascular

Technology Platform

Saturn Transcatheter Mitral Valve Replacement (TMVR) system; a fully percutaneous, transfemoral, transseptal device designed for the complex anatomy of the mitral valve.

Funding History

2
Total raised:$60M
Series B$45M
Series A$15M

Opportunities

The primary opportunity is addressing the massive untreated population of ~1.7 million patients with severe mitral regurgitation in the US/EU who are ineligible for or avoid open-heart surgery, representing a $3.2B+ market.
The commercial success of TAVR provides a validated roadmap for the adoption and reimbursement of transcatheter valve therapies, suggesting strong market potential for a successful TMVR device.

Risk Factors

Key risks include the high technical and clinical failure rate in the challenging mitral valve anatomy, potential complications like LVOTO or paravalvular leak, and the significant capital required to complete pivotal trials.
Regulatory hurdles for a Class III implant and future competition from both other TMVR devices and established repair technologies also pose substantial threats.

Competitive Landscape

InnovHeart operates in the competitive and high-stakes transcatheter mitral valve replacement (TMVR) space. It faces competition from other private and public companies developing TMVR devices (e.g., Cardiovalve, Tendyne [Abbott], Intrepid [Medtronic]), as well as from the established market for transcatheter edge-to-edge repair (TEER) devices like Abbott's MitraClip and Pascal system, which currently dominate the percutaneous mitral intervention market.

More companies in Drug Delivery & Formulation →More companies in Italy →